FDA grants J&J accelerated approval for head and neck cancer treatment

Nov 5 (Reuters) - The US Food and Drug Administration on Thursday granted accelerated approval to Johnson & Johnson's ...
PR Newswire

Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for …

Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate ...
Targeted Oncology

Signatera ctDNA Test Shows Clinical Utility in Head and Neck Cancer

Personalized ctDNA monitoring guides adjuvant therapy and flags head and neck cancer relapse months early, showing high ...
MarketScreener

Natera Announces Clinical Performance of Signatera Test in Head and Neck Squamous Cell Carcinoma

Signatera achieved 100% sensitivity in HPV+ patients, outperforming TTMV-HPV DNA assays commonly used to detect recurrence in this patient population. Signatera-positivity was the only independent ...
BioWorld

A three-armed activator of natural killer cells against head and neck squamous cell carcinoma

Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...

Genmab says head and neck cancer drug cuts death risk by 50% with Merck’s Keytruda

ADRs climbed nearly 15% on Wednesday after the Danish drugmaker said that its bispecific antibody therapy, petosemtamab, in ...